

## Review Form 1.6

Journal Name:	<a href="#">Journal of Pharmaceutical Research International</a>
Manuscript Number:	Ms_JPRI_76975
Title of the Manuscript:	THERAPEUTIC TARGETS IN BREAST CANCER SIGNALING: A REVIEW
Type of the Article	Review

### **General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://peerreviewcentral.com/page/manuscript-withdrawal-policy>)

**Review Form 1.6**

**PART 1: Review Comments**

	<b>Reviewer's comment</b>	<b>Author's comment</b> (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	<p>Breast cancer is one of the most common malignant diseases in women. Although most patients are under management, breast cancer treatment becomes intractable once the cancer cells metastasize. Therefore, the significance of early diagnosis as well as precision medicine is highlighted in breast cancer therapy. This review summarizes the subtypes of breast cancer with distinct genetic traits, such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/neu). The molecular mechanisms of these predominant signaling pathways in tumor progression are elucidated, accompanied by clinically used small molecule inhibitors. Therapeutics for the triple-negative subtype of breast cancer (TNBC) remain an unmet need. This review also provides a better understanding of the heterogeneity of breast cancer.</p> <p>Overall, the authors described the signal pathways of breast cancer and discussed the treatment options and biomarkers based on those pathways. Some of the descriptions are hard to understand. Language needs to be polished before being presented to the readers. Immunotherapy is missed from the review. FDA has approved anti-PD-1 in treating TNBC. Antibody-drug conjugate (ADC) has also shown impressive efficacy in breast cancer treatment, also used in clinics. The author should add another section describing PD-1/PD-L1 signaling in BC treatment.</p>	
<b>Minor</b> REVISION comments	<ol style="list-style-type: none"> <li>1. There are several rules that need to be followed during academic writing. First, be accurate in every statement of scientific evidence. The words used in the manuscript like "perhaps", "usually" and "very" are inappropriate. Second, the descriptions in a review have to be short and clear. For example, "This is why there are various kinds of breast cancer" does not state any valuable information. Third, the scientific terms used in the manuscript need to be consistent with full-name interpretation at the beginning of every abbreviation. Fourth, the arguments delivered in the review require a well-organized context. The arranged order of each subject is not straightforward enough in the current version. Finally, some paraphrased sentences from other publications only use synonyms but lead to ambiguous comprehension.</li> <li>2. Some format is not consistent, such as the paragraph of MAPK pathway. "CDK activating complex and transcriptional CDKs", please delete the extra space.</li> <li>3. Typos appeared throughout the manuscript. For example, "postive hormone receptor" should be "positive hormone receptor"; "C-terminusand" should be "C-terminus and"; "impor tin α-5" should be importin α-5"; "signaling" should be "signalling"; "TGF-an" should be "TGF-α"; "wnt" should be "Wnt"; "oestrogen receptor" should be "estrogen receptor".</li> <li>4. There are some dots before cited reference, like "canonical Wnt. [46]". Please delete them.</li> <li>5. The words in Fig. 2 should be boldly typed.</li> </ol>	
<b>Optional/General</b> comments	<p>The review should also include future perspectives on CAR-T. Although FDA has not approved CAR-T in solid tumor treatment, HER2 is a frequently used target in CAR-T development.</p>	

Review Form 1.6

**PART 2:**

	<b>Reviewer's comment</b>	<b>Author's comment</b> (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Are there ethical issues in this manuscript?</b>	<i>.(If yes, Kindly please write down the ethical issues here in details)</i>	

**Reviewer Details:**

Name:	<b>Chia-Wei Li</b>
Department, University & Country	<b>Institute of Biomedical Sciences, Academia Sinica, Taiwan</b>